We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Newly-Identified Exercise Gene May Treat Depression

By Biotechdaily staff writers
Posted on 17 Dec 2007
Boosting an exercise-related gene in the brain works as a powerful anti-depressant in mice--a finding that could lead to a new anti-depressant drug target.

"The VGF exercise-related gene and target for drug development could be even better than chemical antidepressants because it is already present in the brain,” said Dr. More...
Ronald Duman, professor of psychiatry at Yale School of Medicine (New Haven, CT, USA) and senior author of the study, which was published in the online edition of the journal Nature Medicine on December 2, 2007.

Depression affects 16% of the population in the United States, at a related cost of US$83 billion each year. Currently available anti-depressants help 65% of patients and require weeks to months before the patients experience relief. According to Dr. Duman, it is known that exercise improves brain function and mental health, and provides protective benefits in the event of a brain injury or disease, but how this all occurs in the brain is not well understood. He reported that existing medications take so long to work indicates that some neuronal adaptation or plasticity is needed. He and his colleagues designed a custom microarray that was optimized to show small alteration in gene expression, particularly in the brain's hippocampus, a limbic structure highly sensitive to stress hormones, depression, and anti-depressants.

The researchers then compared the brain activity of sedentary mice to those who were given running wheels. The researchers observed that the mice with wheels within one week were running more than six miles each night. Four independent array analyses of the mice turned up 33 hippocampal exercise-regulated genes--27 of which had never been identified before. The action of one gene in particular--VGF--was greatly enhanced by exercise. Moreover, administering VGF functioned like a powerful anti-depressant, while suppressing VGF inhibited the effects of exercise and induced depressive-like behavior in the mice.

"Identification of VGF provides a mechanism by which exercise produces antidepressant effects,” Dr. Duman said. "This information further supports the benefits of exercise and provides a novel target for the development of new antidepressants with a completely different mechanism of action than existing medications.”


Related Links:
Yale University School of Medicine

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.